Company intelligence / Profile preview

NXTech

Patchogue, New York, USAnxtech.com ↗

Ownership: Private
Development stage: Other

Overview

NXTech has developed a novel digital therapeutic targeting brain pathways crucial for recovery in substance dependency and addiction. The company also offers an integrated electronic control system designed to deactivate fomites and pathogens, with 8 products brought to market as of August 2021. Specific clinical results are not disclosed publicly.

Therapeutic areas: PsychiatryInfectious Diseases
Modalities: Digital therapeuticDevice (electronic control system for optical deactivation)Software (AI algorithms)
Industry: Digital Health Medical Devices

Partnerships

Not publicly disclosed as of August 2021

Beyond the preview

Go deeper on NXTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NXTech.

Explore the full profile